Healthcare - Biotechnology - NASDAQ - US
$ 20.14
-6.93 %
$ 1.6 B
Market Cap
-4.66
P/E
Price Target
Average
69.17%
Revenue Forecast
Estimate
583.92%
EBIT
Estimate
--28.19%
Net Income
Estimate
23.50%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Viridian Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for VRDN of $34.1 , with forecasts ranging from a low of $20 to a high of $56 .
VRDN Lowest Price Target
Wall Street Target
20 USD
-0.70%
VRDN Average Price Target
Wall Street Target
34.1 USD
69.17%
VRDN Highest Price Target
Wall Street Target
56 USD
178.05%
REVENUE FORECAST
Revenue Forecast Chart VRDN
EBIT FORECAST
EBIT Forecast Chart VRDN
NET INCOME FORECAST
Net Income Chart VRDN